Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$753.1m

Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RCKT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Apr 25SellUS$5,139John MilitelloIndividual718US$7.16
10 Apr 25BuyUS$101,600Gaurav ShahIndividual20,000US$5.08
09 Apr 25BuyUS$99,165Kinnari PatelIndividual21,099US$4.70
04 Apr 25SellUS$39,647Aaron OndreyIndividual7,489US$5.29
25 Feb 25SellUS$69,109Jonathan SchwartzIndividual6,532US$10.58
21 Feb 25SellUS$34,089Martin WilsonIndividual3,222US$10.58
21 Feb 25SellUS$172,486Gaurav ShahIndividual16,303US$10.58
21 Feb 25SellUS$28,957John MilitelloIndividual2,737US$10.58
21 Feb 25SellUS$64,305Kinnari PatelIndividual6,078US$10.58
23 Jan 25SellUS$9,300John MilitelloIndividual896US$10.38
21 Nov 24SellUS$144,782Gaurav ShahIndividual11,091US$13.05
21 Nov 24SellUS$15,338Martin WilsonIndividual1,175US$13.05
21 Nov 24SellUS$15,978John MilitelloIndividual1,224US$13.05
21 Nov 24SellUS$59,892Kinnari PatelIndividual4,588US$13.05
21 Nov 24SellUS$154,857Jonathan SchwartzIndividual8,561US$23.35
31 Oct 24SellUS$15,245John MilitelloIndividual917US$16.63
31 Oct 24SellUS$51,205Mark WhiteIndividual3,080US$16.63
16 Aug 24SellUS$73,812Kinnari PatelIndividual3,989US$18.50
16 Aug 24SellUS$19,004Martin WilsonIndividual1,027US$18.50
16 Aug 24SellUS$178,564Gaurav ShahIndividual9,650US$18.50
16 Aug 24SellUS$19,688John MilitelloIndividual1,064US$18.50
22 Jul 24SellUS$18,688John MilitelloIndividual812US$23.02
08 Jul 24SellUS$61,715Mark WhiteIndividual3,026US$20.40
16 May 24SellUS$24,471Martin WilsonIndividual1,048US$23.35
16 May 24SellUS$25,195John MilitelloIndividual1,079US$23.35
16 May 24SellUS$94,474Kinnari PatelIndividual4,046US$23.35
16 May 24SellUS$228,597Gaurav ShahIndividual9,790US$23.35

Insider Trading Volume

Insider Buying: RCKT insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of RCKT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies104,9270.0946%
Individual Insiders2,604,3952.35%
Hedge Funds23,234,94720.9%
Institutions84,995,22376.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.

Top Shareholders

Top 25 shareholders own 77.4% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.4%
RTW Investments, LP
17,687,772US$123.6m0%1.97%
6.75%
BlackRock, Inc.
7,274,190US$50.8m2.49%no data
6.64%
Wellington Management Group LLP
7,151,721US$50.0m-48.9%0.01%
6.14%
The Vanguard Group, Inc.
6,617,784US$46.3m0.61%no data
5.15%
Maverick Capital, Ltd.
5,547,175US$38.8m6.7%0.72%
4.47%
Westfield Capital Management Company, L.P.
4,820,701US$33.7m2.25%0.16%
3.83%
Citadel Advisors LLC
4,122,824US$28.8m91.9%0.03%
3.72%
Janus Henderson Group plc
4,004,039US$28.0m111%0.01%
3.21%
State Street Global Advisors, Inc.
3,458,079US$24.2m11.5%no data
2.92%
T. Rowe Price Group, Inc.
3,148,520US$22.0m-1.85%no data
2.38%
Suvretta Capital Management, LLC
2,566,951US$17.9m0%0.75%
1.63%
Geode Capital Management, LLC
1,752,975US$12.3m8.35%no data
1.48%
Point72 Asset Management, L.P.
1,598,264US$11.2m3,190%0.03%
1.37%
Frazier Life Sciences Management, LP
1,479,025US$10.3m-0.44%0.47%
1.36%
Boxer Capital Management, LLC
1,466,051US$10.2m0%1.03%
1.22%
Pictet Asset Management Limited
1,317,969US$9.2m0%0.01%
1.11%
Avoro Capital Advisors LLC
1,200,000US$8.4m0%0.14%
1.02%
Novo Holdings A/S
1,100,000US$7.7m0%0.01%
1.02%
Cowen Inc,Private Banking and Investment Banking Investments
1,100,000US$7.7m0%0.34%
1.01%
Prosight Management, LP
1,088,706US$7.6m583%2.63%
0.98%
Avidity Partners Management, L.P.
1,053,300US$7.4m40.6%0.87%
0.95%
Gaurav Shah
1,020,631US$7.1m-8.35%no data
0.95%
MPM BioImpact LLC
1,020,559US$7.1m-4.3%1.15%
0.86%
Morgan Stanley, Investment Banking and Brokerage Investments
923,925US$6.5m72.5%no data
0.8%
Medical Strategy GmbH, Asset Management Arm
865,131US$6.0m0%0.43%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 04:53
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity